Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12022720 | 1.00 | LMNA (1.00) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL5390043 | 0.88 | LMNA (0.79) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL5390032 | 0.88 | LMNA (0.79) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL6957180 | 0.87 | LMNA (0.77) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL10427299 | 0.84 | LMNA (0.72) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL10427298 | 0.84 | LMNA (0.72) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL29472125 | 0.83 | LMNA (0.71) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL125972 | 0.83 | LMNA (0.71) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL7399848 | 0.83 | LMNA (0.71) | LMNAALDH1A1HTTPOLBNPC1 | |
| SCHEMBL478339 | 0.83 | LMNA (0.71) | LMNAALDH1A1HTTPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200060997-A1 | TARR Receptor Agonists for Sexual Dysfunction | JOHN MCCOY | 2020-02-27 | — | — | US | claimed |
| US-20160000815-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CT HOLDINGS PTY LTD (AU) | 2016-01-07 | — | — | US | claimed |
| US-20140142140-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2014-05-22 | — | — | US | claimed |
| EP-2729216-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2014-05-14 | — | — | EP | claimed |
| WO-2013007698-A1 | PHARMACEUTICAL COMPOSITION FOR NEUROLOGICAL DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2013-01-17 | — | — | WO | claimed |
| JP-2011529923-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110207718-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD. (AU) | 2011-08-25 | — | — | US | claimed |
| EP-2331088-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | Gosforth Centre (Holdings) Pty Ltd (AU) | 2011-06-15 | — | — | EP | claimed |
| WO-2010015029-A1 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC DISORDERS | GOSFORTH CENTRE (HOLDINGS) PTY LTD (AU) | 2010-02-11 | — | — | WO | claimed |
| WO-2026106796-A1 | SYSTEM AND METHOD FOR THE TREATMENT OF TELOGEN EFFLUVIUM, ANDROGENETIC ALOPECIA, AND OTHER HAIR LOSS DISORDERS | FOLLEA INTERNATIONAL (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INT (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| WO-2024118094-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | FOLLEA INTERNATIONAL (US) | 2024-06-06 | — | — | WO | disclosed |
| US-7247688-B2 | Method for synthesis of block polymers by controlled free radical polymerization | RHODIA CHIMIE (FR) | 2007-07-24 | — | — | US | disclosed |
| US-20070027266-A1 | Oxidizing one or more thiocarbonylthio ends of a polymer resulting from a radical polymerization controlled by reversible addition-fragmentation using thiocarbonylthio by reacting with ozone | SPECIALTY OPERATIONS FRANCE (FR) | 2007-02-01 | — | — | US | disclosed |
| US-20070027266-A1 | Oxidizing one or more thiocarbonylthio ends of a polymer resulting from a radical polymerization controlled by reversible addition-fragmentation using thiocarbonylthio by reacting with ozone | SPECIALTY OPERATIONS FRANCE (FR) | 2007-02-01 | — | — | US | disclosed |
| US-6410749-B1 | REACTING A CARBONYL COMPOUND WITH ORGANOMETALLIC COMPOUND | NIPPON SODA CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1146037-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS | NIPPON SODA CO., LTD. (JP) | 2001-10-17 | — | — | EP | disclosed |
| US-3971772-A | ANTINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041652-A1 | SYSTEM AND METHOD FOR PREVENTING ALOPECIA | DYRK4, DYRK2, STRA6 | LMNA 2196/4885ALDH1A1 4003/4885HTT 125/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | LMNA 173/4885ALDH1A1 1640/4885HTT 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.